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Introduction {#sec005}
============

According to the National Center for Health Statistics, heart disease is the leading cause of death in the United States \[[@pone.0235277.ref001]\]. The World Health Organization has also indicated that cardiovascular disease (CVD) is the number one cause of death globally \[[@pone.0235277.ref002]\], causing great loss and heavy burden in society \[[@pone.0235277.ref003]\]. There have been many attempts to predict CVD risk \[[@pone.0235277.ref004]\], and the Framingham Heart Study has been the most famous system for prediction \[[@pone.0235277.ref005]\]. Physical activity has been shown to reduce CVD risk in both women and men \[[@pone.0235277.ref006]--[@pone.0235277.ref008]\], and walking speed could be one of the simple and reliable ways to predict CVD risk \[[@pone.0235277.ref009]\]. Regular exercise has also been recognized as an important factor in reducing the Framingham risk score in patients with metabolic syndrome \[[@pone.0235277.ref010]--[@pone.0235277.ref012]\]. Physical activity could serve as a protective factor and an indicator for CVD. However, previous research has mainly focused on the relationship between walking speed and CVD risk only. Our research was the first community-based study that aimed to reveal the role of age in the relationship of walking speed and CVD risk.

Materials and methods {#sec006}
=====================

Study design and participants {#sec007}
-----------------------------

This was a cross-sectional and community-based study. Before this study, the minimum sample size for this study was calculated at the initial stage of the study after previewing a relatively smaller population. Considering an 85% power, a 95% confidence level, and 0.30 as the high CVD risk rate among middle-aged people, we calculated that 288 participants were required to detect differences between these two study groups with an odds ratio of at least 2. We recruited 400 participants aged 50 years and over from a community health promotion project in 2014 in Guishan district, Taoyuan city. We excluded 91 participants who (1) had a history of CVD, (2) were unable to complete a 6-meter-long walk, and (3) were over 75 years old ([Fig 1](#pone.0235277.g001){ref-type="fig"}). A total of 309 participants were eligible for analysis and were divided into three groups based on three levels of CVD risk: low, medium, and high. Each participant completed a questionnaire that included personal information and a medical history during a face-to-face interview. Furthermore, they completed a laboratory measurement and a 6-meter walking speed test. The study was approved by the Chang-Gung Medical Foundation Institutional Review Board (102-2304B), and all the participants were fully informed and signed informed consent forms before enrollment.

![Flow chart of study subjects.](pone.0235277.g001){#pone.0235277.g001}

Data collection and laboratory measurements {#sec008}
-------------------------------------------

The content of the questionnaire included sex, age, alcohol drinking status (drinking ≥2 days/week or not) and current smoking status (current smoker or not). The health survey contained hypertension (HTN), diabetes mellitus (DM), and dyslipidemia data. Resting systolic and diastolic blood pressure (BP, mmHg) were measured at least two times at rest. The biochemical laboratory data were analyzed at the central laboratory of Linkou Chang Gung Memorial Hospital, including low density lipoprotein (LDL-C, mg/dl), total cholesterol (TC, mg/dl), high-density lipoprotein (HDL-C, mg/dl), triglyceride (TG, mg/dl), waist circumference (WC, cm), alanine transaminase (ALT, mg/dl), creatinine (mg/dl), fasting plasma glucose (FPG, mg/dl), and uric acid (mg/dl). WC was measured at the midpoint between the inferior margin of the last rib and the iliac crest in a horizontal plane in an upright position. We also measured the time (in seconds) it took for participants to walk 6 meters in a straight line to obtain the walking speed data.

Definition of CVD risk {#sec009}
----------------------

In this study, the general CVD risk model from the Framingham Heart Study was used for predicting CVD risk, which included several variables, such as age, sex, systolic BP, anti-HTN medication, current smoking status, DM, TC, and HDL-C \[[@pone.0235277.ref013]\]. DM was defined as an FPG ≥ 126 mg/dL or the use of oral hypoglycemic agents or insulin therapy. HTN was defined as systolic BP ≥ 140 mmHg, diastolic BP ≥ 90 mmHg, or the use of treatment for HTN.Dyslipidemia was defined as LDL-C ≥ 130 mg/dL, HDL-C \< 40 mg/dL in males or \< 50 mg/dL in females, TG ≥ 150 mg/dL, TC ≥ 200 mg/dL, or the use of lipid-lowering medication. Current smoking status was recorded by self-report. We further divided our participants into a low CVD risk group (Framingham Risk Score \[FRS\] \< 10%), a medium-risk group (10% ≤ FRS \< 20%), and a high-risk group (FRS ≥ 20%).

Statistical analysis {#sec010}
--------------------

Participants were divided into three groups according to three levels of CVD risk: low, medium, and high. For the laboratory and clinical data of each group, continuous variables were expressed as the mean ± SD and were analyzed by one-way ANOVA. Categorical variables were expressed as n (%) and analyzed with a chi-square test. In addition, participants were divided into a middle-aged group and an elderly group according to age. Pearson's correlation coefficient was used to analyze correlations between walking speed and TC, HDL, LDL, TG, FPG, uric acid, WC, and FRS scores in each group. Finally, the multivariate logistic regression model for predicting CVD risk and walking speed was adjusted for sex, age, WC, HTN, DM, and hyperlipidemia in each group. In our study, a p-value of \< 0.05 was considered statistically significant. All statistical analyses were performed using SPSS for Windows (IBM Corp. Released 2011. IBM SPSS Statistics, version 20.0. Armonk, NY: IBM Corp.)

Results {#sec011}
=======

The 309 participants were 50-74(62.05 ± 6.21) years old and consisted of 98 males (31.7%) and 211 females (68.3%) with no CVD history. The general characteristics of the study participants are shown in [Table 1](#pone.0235277.t001){ref-type="table"}. There were significantly more males than females with a high CVD risk, and there were significant increases in age, current smoking status, HTN, DM, SBP, DBP, and HDL-C in the group with a higher CVD risk. Other parameters that also increased with higher CVD risk were TG, WC, creatinine, FPG, and uric acid. There was no significant difference in LDL-C or TC among the three groups. The walking speeds of the low, medium and high CVD risk groups were 1.05 ± 0.31, 0.98 ± 0.24, and 0.94 ± 0.28, respectively. The differences among the three groups were statistically significant. The walking speed gradually decreased from the low CVD risk group to the high CVD risk group (p \< 0.05). In [Table 2](#pone.0235277.t002){ref-type="table"} and [Table 3](#pone.0235277.t003){ref-type="table"}, participants were divided into two groups according to age. Those older than or equal to 50 years old and younger than 65 years old were in the middle-aged group, and those older than 65 years old were in the elderly group.

10.1371/journal.pone.0235277.t001

###### The characteristics of study subjects categorized by CVD risk.

![](pone.0235277.t001){#pone.0235277.t001g}

  **Variables**            **Low risk (n = 139)**   **Moderate risk (n = 99)**   **High risk (n = 71)**   **p value**
  ------------------------ ------------------------ ---------------------------- ------------------------ -------------
  Sex (male), n(%)         11 (7.9)                 33 (33.3)                    54 (76.1)                \<0.001
  Age (years)              59.1 ± 5.4               64.7 ± 6.1                   64.1 ± 5.4               \<0.001
  Alcohol drinking, n(%)   20 (14.4)                18 (18.2)                    21 (29.6)                0.029
  Current Smoking, n(%)    2 (14.4)                 6 (6.1)                      23 (32.4)                \<0.001
  Hypertension, n(%)       34 (24.5)                60 (60.6)                    53 (74.6)                \<0.001
  Diabetes, n(%)           12 (8.6)                 15 (15.2)                    28 (39.4)                \<0.001
  Dyslipidemia, n(%)       78 (56.1)                67 (67.7)                    54 (76.1)                0.012
  walking speed (m/s)      1.05 ± 0.31              0.98 ± 0.24                  0.94 ± 0.28              0.03
  WC (cm)                  81.1 ± 7.7               84.5 ± 8.4                   91.0 ± 10.2              \<0.001
  SBP (mmHg)               121.3 ± 12.6             132.6 ± 14.6                 138.1 ± 17.9             \<0.001
  DBP (mmHg)               74.4 ± 9.4               79.1 ± 10.9                  84.1 ± 11.1              \<0.001
  LDL-C (mg/dl)            116.3 ± 30.5             123.8 ± 33.2                 120.1 ±33.3              0.209
  TC (mg/dl)               197.3 ± 33.3             203.4 ± 36.3                 196.4 ± 36.7             0.324
  HDL-C (mg/dl)            60.3 ± 13.3              54.6 ± 13.1                  45.9 ± 9.5               \<0.001
  TG (mg/dl)               103.1 ± 47.2             125.6 ± 60.8                 152.4 ± 78.0             \<0.001
  ALT (mg/dl)              21.1 ± 8.8               22.4 ± 13.5                  27.0 ± 17.4              0.006
  Creatinine (mg/dl)       0.65 ± 0.27              0.74 ± 0.21                  0.86 ± 0.37              \<0.001
  FPG (mg/dl)              90.0 ± 12.6              96.7 ± 24.3                  105.7 ± 29.2             \<0.001
  Uric acid (mg/dl)        5.4 ± 1.1                5.7 ± 1.4                    6.4 ± 1.7                \<0.001
  CVD risk (%)             6.2 ± 2.2                14.0 ± 2.6                   30.2 ± 11.8              \<0.001

(low risk group:FRS\< 10%, moderate risk group:10% ≤ FRS \<20%, high risk group:FRS ≥ 20%; FRS = Framingham Risk Score).

(Data expressed as mean ± SD for continuous variables and n (%) for categorical variables).

(Data analyzed with One-way ANOVA for continuous variables and chi-squared test for categorical variable).

(The definition of low, moderate and high risk are FRS \< 10%, 10% ≤ FRS \<20% and FRS ≥ 20% respectively).

Abbreviations: SBP = systolic blood pressure; DBP = diastolic blood pressure; TC = total cholesterol; LDL-C = low density lipoprotein; HDL-C = high density lipoprotein; TG = triglyceride; WC = waist circumference; ALT = alanine transaminase; FPG = fasting plasma glucose; FRS score = Framingham Risk Score.

10.1371/journal.pone.0235277.t002

###### Pearson's correlation coefficients (r) between walking speed and CVD risk factors.
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  Variables           Walking speed (m/s)                           
  ------------------- --------------------------------------------- ---------------------------------------------
  TC (mg/dl)          0.036                                         -0.117
  HDL (mg/dl)         0.143[\*](#t002fn002){ref-type="table-fn"}    -0.065
  LDL (mg/dl)         -0.074                                        -0.132
  TG (mg/dl)          -0.089                                        -0.077
  FPG (mg/dl)         -0.009                                        -0.062
  Uric acid (mg/dl)   -0.045                                        -0.219[\*](#t002fn002){ref-type="table-fn"}
  WC (cm)             -0.004                                        0.014
  CVD risk (%)        -0.143[\*](#t002fn002){ref-type="table-fn"}   -0.032

r = correlation coefficients,

\* = p value \< 0.05.

Abbreviations: TC = total cholesterol; LDL-C = low density lipoprotein; HDL-C = high density lipoprotein; TG = triglyceride; FPG = fasting plasma glucose; WC = waist circumference; CVD risk was measured by Framingham Risk Score (FRS).

10.1371/journal.pone.0235277.t003

###### Odds Ratio (OR) for moderate to high CVD risk according to walking speed.
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  Walking speed   Middle-aged (n = 209)   Elderly (n = 100)                             
  --------------- ----------------------- ------------------- ------------------------- -------
  Model 1         0.346 (0.125--0.961)    0.046               2.523 (0.363--17.524)     0.349
  Model 2         0.276 (0.078--0.984)    0.047               3.329 (0.321--34.540)     0.314
  Model 3         0.127 (0.021--0.771)    0.025               27.259 (0.752--987.664)   0.071

(data expressed as OR and 95% confidence interval(CI)).

Odds Ratios for walking speed by FRS score, separating to FRS \< 10% and FRS≥10% two groups.

†Model 1: unadjusted; Model 2: adjusted for sex and age; Model 3: adjusted for sex, age, waist circumference, hypertension, diabetes mellitus and hyperlipidemia.

In [Table 2](#pone.0235277.t002){ref-type="table"}, the walking speed of the middle-aged group showed negative relationships with LDL, TG, FPG, uric acid, and CVD risk but showed positive relationships with TC and HDL. Only the relationships between walking speed and HDL and CVD risk reached statistical significance in middle-aged people. On the other hand, the walking speed of the elderly group showed negative relationships with TC, HDL, LDL, TG, FPG, uric acid, and CVD risk but showed a positive relationship with WC. Only the relationship between walking speed and uric acid reached statistical significance in elderly people. A significant inverse association between walking speed and FSR was confirmed with a Pearson's correlation coefficient of -0.143 (p \< 0.05) in middle-aged people rather than in elderly people.

In [Table 3](#pone.0235277.t003){ref-type="table"}, three multiple logistic regression models were used to calculate the OR of walking speed with CVD risk under adjustment for other risk factors. Model 1 was unadjusted; model 2 was adjusted for sex and age; and model 3 was adjusted for sex, age, WC, HTN, DM, and hyperlipidemia. The p-values of both groups decreased when considering more factors in the multiple logistic regression model, and only the p-values of the middle-aged group remained statistically significant in all three models. In particular, in model 3, the p-value of the middle-aged group reached 0.025 as the minimum value in [Table 3](#pone.0235277.t003){ref-type="table"}, indicating the strongest relationship between walking speed and CVD risk. The multivariate logistic regression model for predicting CVD risk and walking speed showed an adjusted OR of 0.127 (95% CI = 0.021--0.771) in middle-aged people with adjustment for sex, age, WC, HTN, DM, and hyperlipidemia. It also confirmed the strongest relationship between walking speed and CVD risk in middle-aged people (p \< 0.05) rather than in elderly people.

Discussion {#sec012}
==========

In this community-based cross-sectional study, we aimed to discuss the association between walking speed and CVD risk in people older than 50 years of age, and we found evidence that the risk of CVD was highly related to walking speed in people between the ages of 50 and 65 but not in people over 65 years of age.

In [Table 1](#pone.0235277.t001){ref-type="table"}, we used FRS as a CVD risk measurement to categorize participants into three groups: the low CVD risk group (FRS \< 10%), medium-risk group (10% ≤ FRS \< 20%), and high-risk group (FRS ≥ 20%). We compared laboratory data and all participants' lifestyles in [Table 1](#pone.0235277.t001){ref-type="table"}. The risk factors for cardiovascular risk were sex, age, systolic pressure, HTN, current smoking status, DM, HDL-C and TC, as shown in [Table 1](#pone.0235277.t001){ref-type="table"}. Men had a higher CVD risk than women, and this result corresponds to the fact that men have a higher cardiovascular risk \[[@pone.0235277.ref014]\]. Old age is another important risk factor for CVD \[[@pone.0235277.ref015]\], and our study showed that older people had a higher CVD risk. HTN and high systolic pressure also play important roles in CVD. High BP usually elevates CVD risk and increases CVD morbidity \[[@pone.0235277.ref016]\], and high systolic pressure was positively correlated with high CVD risk in our study. Smoking-induced vessel damage is also associated with CVD \[[@pone.0235277.ref017]\], and DM is another risk factor for myocardial ischemia and CVD \[[@pone.0235277.ref018]\], both of which were related to elevated CVD risk in this study. On the other hand, HDL-C is a protective factor for CVD \[[@pone.0235277.ref019]\]. Therefore, this study showed that a lower CVD risk tended to result in a higher level of HDL-C. Although high cholesterol levels are linked to elevated CVD risk \[[@pone.0235277.ref020]\], there was no significant difference found in our study, as shown in [Table 1](#pone.0235277.t001){ref-type="table"}.

[Table 1](#pone.0235277.t001){ref-type="table"} shows a significant difference in the group with high FRS with a lower walking speed (p = 0.03). [Table 2](#pone.0235277.t002){ref-type="table"} focuses on the relationship between age and walking speed and shows a strong negative relationship. Participants over 50 years old were divided into two groups: those older than or equal to 50 years old but below 65 years old were in the middle-aged group, and those older than 65 years old were in the elderly group. The walking speed of the two groups was negatively correlated with LDL, TG, FPG, uric acid, and CVD risk; only the walking speed of the middle-aged group showed a positive correlation and reached statistical significance. This result indicates that walking speed is closely related to CVD risk in middle-aged people rather than in elderly people.

There are many factors that can weaken the physical activity of middle-aged and elderly people. The models were adjusted for all the factors listed in [Table 3](#pone.0235277.t003){ref-type="table"} to analyze their impact on the relationship between walking speed and CVD risk. There were three models to adjust the ORs between walking speed and CVD risk. Model 1 was unadjusted, and the ORs of the middle-aged group and the elderly group were 0.246 and 2.523, respectively, but only the OR of the middle-aged group reached statistical significance, showing that walking speed is highly associated with CVD risk in middle-aged people. Model 2 was adjusted for age and sex, and model 3 was adjusted for sex, age, WC, HTN, DM, and hyperlipidemia. The OR in the middle-aged group was statistically significant in both model 2 and model 3, and the p-value decreased when more factors were adjusted in model 3, indicating that walking speed is a powerful indicator of CVD risk in the middle-aged group. On the other hand, the OR never reached statistical significance in the models of elderly people, although the p-value decreased when more factors were adjusted, indicating that there are more potential factors that can affect the relationship of walking speed and CVD risk. There are some physical challenges related to advanced age that can be potential factors affecting walking speed, such as arthritis, chronic obstructive pulmonary disease, and sarcopenia \[[@pone.0235277.ref021]--[@pone.0235277.ref024]\]. These physical challenges may explain why the elderly group did not show a strong negative relationship between walking speed and CVD risk. However, we did not discuss the potential factors in this study. Therefore, this study indicates that walking speed alone can be a predictor of CVD risk in the middle-aged population, but for the elderly population, there are more factors to be considered. In [Table 4](#pone.0235277.t004){ref-type="table"}, previous research has mainly focused on the relationship between walking speed and CVD risk \[[@pone.0235277.ref025]--[@pone.0235277.ref028]\] in other countries. Our research was the first community-based study that examined the role of age in the relationship between walking speed and CVD risk in Taiwan. Thus, the novel findings of this study are the first to explore the association between CVD risk and walking speed in different age populations in Taiwan. Second, we conducted a community-based study and comprehensively collected various data from a health promotion project, which may have clinical implications.

10.1371/journal.pone.0235277.t004

###### Comparison with the other recent epidemiological studies in the similar field.
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  Title                                                                                                                                                         Author                  Date   Study design                         Finding
  ------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------- ------ ------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------
  Slow walking speed and cardiovascular death in well functioning older adults: prospective cohort study \[[@pone.0235277.ref025]\]                             Julien Dumurgier.etc    2009   prospective cohort study             lower walking speed was strongly associated with cardiovascular mortality in a populationof well functioning older people.
  Association of walking speed in late midlife with mortality: results from the Whitehall II cohort study \[[@pone.0235277.ref026]\]                            Alexis Elbaz.etc        2013   cohort study                         slow walking speed during late midlife is associated with increased mortality over 6 years of follow-up
  Objective measures of the frailty syndrome (hand grip strength and gait speed) and cardiovascular mortality: A systematic review \[[@pone.0235277.ref027]\]   Vinod Chainani.etc      2016   A systematic review                  both gait speed and hand grip strength are associated with increased risk of cardiovascular mortality in diverse populations.
  Treadmill walking speed and survival prediction in men with cardiovascular disease: a 10-year follow-up study \[[@pone.0235277.ref028]\]                      Giorgio Chiaranda.etc   2013   Population-based prospective study   1 km treadmill walking test at a moderate intensity is a useful tool for identifying mortality risk in patients with stable cardiovascular disease.

However, our study still had limitations. The participants in our study were recruited from a relatively small group in northern Taiwan as our favored population. The characteristics of the residents from this small group might differ from characteristics in the general population, so the findings cannot be generalized to the whole middle-aged and elderly population in Taiwan. Selection bias should be considered, and the results of our study should not be extrapolated to other regions of Taiwan. Future studies using random sampling of communities with a wider range of regions would make the research more discursive.

Conclusion {#sec013}
==========

Our study shows that slow walking speed is highly associated with high CVD risk in middle-aged people. However, as discussed above, there are more factors that lead to a decline in exercise capacity or an increased risk of CVD in elderly individuals. In conclusion, using walking speed alone to predict CVD risk can only be used in middle-aged people because there are more factors to be considered in elderly people. Thus, our findings may provide valuable information for clinicians to alert middle-aged people regarding the increased risk of CVD.

10.1371/journal.pone.0235277.r001
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Responses to reviewers' comments

Reviewer 1

Comment\#1

Please give the power of data collection.

Response\#:1

We thank the reviewer for reminding us this important issue. The sample size determination was based on the G\*power 3.1 software. We did calculate the minimum sample size before this study. We also added statements to explain the calculation in study design and participants. These statements read as: "Before this study, the minimum sample size for this study was calculated at the initial stage of the study after previewing a relatively smaller population. Considering an 85% power, a 95% confidence level, and 0.30 as the high CVD risk rate among middle-aged people, we calculated that 288 participants were required to detect differences between these two study groups with an odds ratio of at least 2." (Lines 79-83).

1\. Jacob C, Statistical power analysis for the behavioral sciences. International Biometric Society, 1988.

Comment\#2

Flow chart of selection of the study sample and procedure is suggested

Response\#:2

Thanks for the reviewer's suggestion, we made the flow chart in response to this comment (Please see Appendix 1), and put it in manuscript as Figure 1.

Comment\#3

A statement including the reference number of the ethics committee where appropriate should appear in the manuscript.

Response\#:3

We thank the reviewer for reminding us this important issue. In response to this comment, the reference number is 102-2304B and we add it into our manuscript in study design and participants, which read as" The study was approved by the Chang-Gung Medical Foundation Institutional Review Board (102-2304B), and all the participants were fully informed and signed informed consent forms before enrollment." (Lines 90-92)

Comment\#4

From the epidemiologic viewpoint, there are many confounding factors in the evidenced-based researches. How the authors deal with associated confounding factors in this study?

Response\#:4

Thanks for the reviewer's viewpoint. We deal those confounding factor with logistic regression in Table 3. Sex, age, waist circumference, hypertension, diabetes mellitus and hyperlipidemia were used for adjustment. We add material in statistical analysis, which read as "Finally, the multivariate logistic regression model for predicting CVD risk and walking speed was adjusted for sex, age, WC, HTN, DM, and hyperlipidemia in each group." (lines 154-155), and we add another material in result, which read as "The multivariate logistic regression model for predicting CVD risk and walking speed with an adjusted odds ratio (OR) was 0.127 (95% CI = 0.021-0.771) in middle-aged people with adjustment for sex, age, waist circumference (WC), hypertension (HTN), diabetes mellitus (DM), and hyperlipidemia (p \< 0.05)." (lines 53-57)

Comment\#5

The authors should point and clarify the feature and novel findings of this study.

Response\#:5

We fully agree with the reviewer's comment about novelty finding of our study, we have added statements in discussion, which read as: "Previous research has mainly focused on the relationship between walking speed and CVD risk \[25\] \[26\] \[27\] \[28\] in other countries. Our research was the first community-based study that examined the role of age in the relationship between walking speed and CVD risk in Taiwan. Thus, the novel findings of this study are the first to explore the association between CVD risk and walking speed in different age populations in Taiwan. Second, we conducted a community-based study and comprehensively collected various data from a health promotion project, which may have clinical implications." (Lines 299-305).

Comment\#6

Please consider the comparison with the other epidemiological studies in other areas using table so make clear the significance of this study.

Response\#:6

We appreciate the reviewer's comments and made a chart to compare with recent publication, and put it in manuscript as Table 4:

title author date Study design finding

Slow walking speed and cardiovascular death in well functioning older adults: prospective cohort study Julien Dumurgier.etc 2009 prospective cohort study lower walking speed was strongly associated with cardiovascular mortality in a population of well functioning older people.

Association of walking speed in late midlife with mortality: results from the Whitehall II cohort study Alexis Elbaz.etc 2013 cohort study slow walking speed during late midlife is associated with increased mortality over 6 years of follow-up

Objective measures of the frailty syndrome (hand grip strength and gait speed) and cardiovascular mortality: A systematic review Vinod Chainani.etc 2016 A systematic review both gait speed and handgrip strength are associated with increased risk of cardiovascular mortality in diverse populations.

Treadmill walking speed and survival prediction in men with cardiovascular disease: a 10-year follow-up study Giorgio Chiaranda.etc 2013 Population-based prospective study 1 km treadmill walking test at a moderate intensity is a useful tool for identifying mortality risk in patients with stable cardiovascular disease.

Comment\#7

The results of goodness-of-test in table 3 are suggested.

Response\#:7

We appreciate the suggestion from reviewer. According to the p-value for hosmer and lemeshow goodness-of-fit test＞0.05

Comment\#8

The authors should add the comments related to selection bias in this study to the perceived limitation subsection.

Response\#:8

We fully agree with the reviewer regarding the fact that our findings were obtained from community-based subjects and cannot be generalized to the whole middle-aged and elderly population in Taiwan. To response to the reviewer's comment, this limitation has been acknowledged in the discussion section, which read as "However, our study still had limitations. The participants in our study were recruited from a relatively small group in northern Taiwan as our favored population. The characteristics of the residents from this small group might differ from characteristics in the general population, so the findings cannot be generalized to the whole middle-aged and elderly population in Taiwan. Selection bias should be considered, and the results of our study should not be extrapolated to other regions of Taiwan. Future studies using random sampling of communities with a wider range of regions would make the research more discursive." (Lines 306-312).

Comment\#9

More discussion regarding the policy implications of their findings would be important for the use of methodology in health policy making.

Response\#:9

We thank the reviewer for this comment. We have added statements in the conclusion section for suggestions for further clinical practice of the results. These statements read as: "Thus, our findings may provide valuable information for clinicians to alert middle-aged people regarding the increased risk of CVD." (Lines 319-320).

Comment\#10

Some references should be updated.

Response\#:10

In response to the reviewer's suggestion, we have replaced some old references, those references are in number 11,18,21,22, and add extra reference for citation, those reference are in 25,16,27,28. Accordingly, we have changed the sequence of citations in the text.

Reviewer 2

Comment:

The authors aimed to evaluate the walking speed for predicting cardiovascular disease (CVD) risk in middle-aged and elderly people. I am interested in this topic, however, the data is mainly collected from a specific community. Why did the authors choose the residents living in Guishan district to be enrolled in their study? Can this small group represent and draw conclusion in whole middle-aged and elderly population of Taiwan including the downtown, suburban, and rural areas?

Response\#:

We appreciate the reviewer's concern. This is a community-based study, so we chose the participants living in Guishan district for convenient and selective sampling. The resident from this district might have different characteristics comparing with the general population, and we only recruit participants from this district in northern Taiwan as our favor population. Thus, the results can not represent the other regions of Taiwan. Future studies using random sampling of communities with wider range of area would make the research more robust. To response to the reviewer's concern, this limitation has been acknowledged in the discussion section, which read as "However, our study still had limitations. The participants in our study were recruited from a relatively small group in northern Taiwan as our favored population. The characteristics of the residents from this small group might differ from characteristics in the general population, so the findings cannot be generalized to the whole middle-aged and elderly population in Taiwan. Selection bias should be considered, and the results of our study should not be extrapolated to other regions of Taiwan. Future studies using random sampling of communities with a wider range of regions would make the research more discursive." (Lines 306-312).

General Comments:

I applaud the authors for their effort, however, the syntax, grammar and overall style of this manuscript is sometimes difficult to read and needs a robust editing from a fluent or native English speaker. For instance, in Introduction section, last sentence: "and elderly poeple." is an obvious typo error. I suggest the authors to have the manuscript carefully proofread again to correct grammar and other errors.

Response to General Comments:

We thank the reviewer for reminding us this important issue. We had found a native English speaker to help us to edit our manuscript before we resubmitted it, and the English editing certificate was provided. (Please see Appendix 2)

Major Comment 1:

Please revise the title of your manuscript so that it contains details of the study design which characterize the investigation as well. Please provide more information on the novelty of your study. Introduction should finish with the aim of the study that should be described more clearly.

Response to Major Comment 1:

We appreciate the suggestion form reviewer. After we revised our manuscript, the title was rewrote as suggested in cover page. The title now reads as: "The Association between Walking Speed and Risk of Cardiovascular Disease in Middle-aged and Elderly people in Taiwan, a community-based, cross-sectional study".

We fully agree with the reviewer's comment about novelty finding of our study, we have added statements in discussion, which read as: "Previous research has mainly focused on the relationship between walking speed and CVD risk \[25\] \[26\] \[27\] \[28\] in other countries. Our research was the first community-based study that examined the role of age in the relationship between walking speed and CVD risk in Taiwan. Thus, the novel findings of this study are the first to explore the association between CVD risk and walking speed in different age populations in Taiwan. Second, we conducted a community-based study and comprehensively collected various data from a health promotion project, which may have clinical implications." (Lines 299-305).

According reviewer's helpful suggestion, we also modified our aim in the introduction, which read as "However, previous research has mainly focused on the relationship between walking speed and CVD risk only. Our research was the first community-based study that aimed to reveal the role of age in the relationship of walking speed and CVD risk." (lines 72-75)

Major Comment 2:

There were total 400 participants in the project, which was a relatively small sample size. Sample size should be increased to claim scientific merits of your study. The claims made by authors are significantly weakened by the fact that they are talking about findings drawn from a small sample size, and then should have mentioned this as limitation without any justification. Did you calculate the sample size before the investigation and what should be the minimal sample size needed in this study to avoid underpowered? Could the authors show the power of their sample size?

Response to Major Comment 2:

We fully agree with the reviewer regarding the fact that our findings were obtained from community-based subjects and cannot be generalized to the whole middle-aged and elderly population in Taiwan. To response to the reviewer's comment, this limitation has been acknowledged in the discussion section, which read as "However, our study still had limitations. The participants in our study were recruited from a relatively small group in northern Taiwan as our favored population. The characteristics of the residents from this small group might differ from characteristics in the general population, so the findings cannot be generalized to the whole middle-aged and elderly population in Taiwan. Selection bias should be considered, and the results of our study should not be extrapolated to other regions of Taiwan. Future studies using random sampling of communities with a wider range of regions would make the research more discursive." (Lines 306-312). We also calculated sample size with G\*power 3.1 software before this study. We did calculate the minimum sample size. We also added statements to explain the calculation in study design and participants. These statements read as: "Before this study, the minimum sample size for this study was calculated at the initial stage of the study after previewing a relatively smaller population. Considering an 85% power, a 95% confidence level, and 0.30 as the high CVD risk rate among middle-aged people, we calculated that 288 participants were required to detect differences between these two study groups with an odds ratio of at least 2." (Lines 79-83).

1\. Jacob C, Statistical power analysis for the behavioral sciences. International Biometric Society, 1988.

Major Comment 3:

Please indicate the selection of study participants by adding a CONSORT diagram with flow chart.

Response\# Major Comment 3:

Thanks for the reviewer's suggestion, we made the flow chart in response to this comment (Please see Appendix 1) ,and put it in manuscript as Figure 1.

Major Comment 4:

The Introduction and Discussion sections need to be expanded with improvements. Try to cite more references to support your Result. Moreover, some of the references are outdated. Please update your reference list.

Response\# Major Comment 4:

In response to the reviewer's suggestion, we add material in introduction, which read as" However, previous research has mainly focused on the relationship between walking speed and CVD risk only. Our research was the first community-based study that aimed to reveal the role of age in the relationship of walking speed and CVD risk." (Line 72-75), we add material in discussion, which read as" Previous research has mainly focused on the relationship between walking speed and CVD risk \[25\] \[26\] \[27\] \[28\] in other countries. Our research was the first community-based study that examined the role of age in the relationship between walking speed and CVD risk in Taiwan. Thus, the novel findings of this study are the first to explore the association between CVD risk and walking speed in different age populations in Taiwan. Second, we conducted a community-based study and comprehensively collected various data from a health promotion project, which may have clinical implications. However, our study still had limitations. The participants in our study were recruited from a relatively small group in northern Taiwan as our favored population. The characteristics of the residents from this small group might differ from characteristics in the general population, so the findings cannot be generalized to the whole middle-aged and elderly population in Taiwan. Selection bias should be considered, and the results of our study should not be extrapolated to other regions of Taiwan. Future studies using random sampling of communities with a wider range of regions would make the research more discursive." (Line 299-305, 306-312) We also have replaced some old references, those references are in number 11,18,21,22, and add extra reference for citation, those reference are in 25,16,27,28. Accordingly, we have changed the sequence of citations in the text.

Appendix 1.

\<please see the file \"response 2 edited\"\>

Appendix 2.

\<please see the file \"response 2 edited\"\>

###### 

Submitted filename: response 3 edited dechart.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0235277.r003

Decision Letter 1

Kou

Yu Ru

Academic Editor

© 2020 Yu Ru Kou

2020

Yu Ru Kou

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

12 Jun 2020

The Association between Walking Speed and Risk of Cardiovascular Disease in Middle-aged and Elderly people in Taiwan, a community-based, cross-sectional study

PONE-D-20-04269R1

Dear Dr. Chen,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Yu Ru Kou, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**
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Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*
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